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ABSTRACT 
Objective: To develop novel, simple and rapid enantiomeric separation of Etodolac by reverse-phase high-performance liquid chromatographic 
method as per ICH guidelines. 
Methods: The R-isomer and S-isomer were baseline resolved on a CHIRAL-AGP, (100 x 4.0 mm i. d, 5 µm) column using a mobile phase system 
containing 0.1 M sodium dihydrogen phosphate dihydrate pH 4.0 buffer: Isopropanol (85:15 v/v.) at detector wavelength 225 nm and column 
temperature 25 °C. The chromatographic resolutions between R-isomer and S-isomer were found three. The developed method was extensively 
validated according to ICH guidelines. 
Results: Good linearity was observed for R-isomer over the concentration range of 300–3000 ng/ml, with the linear regression (Correlation 
coefficient R = 0.999) and proved to be robust. The limit of detection and limit of quantification of R-isomer was found to be 300 and 900 ng/ml, 
respectively for 10 µl injection volume. The percentage recovery of R-isomer was ranged from 98.0 to 102.0 in bulk drug samples of Etodolac. 
Etodolac sample solution and mobile phase were found to be stable for at least 48 hours. The proposed method was found to be suitable and 
accurate for the quantitative determination of R-isomer in bulk drugs.  
Conclusion: A novel, simple and rapid enantiomeric separation of Etodolac by reverse-phase high-performance liquid chromatographic method 
was developed and validated as per ICH guidelines. The developed method can be used for the quantitative determination R-isomer in bulk drug 
materials in pharmaceutical industry. 
Keywords: Etodolac, Reverse phase, Chiral HPLC, Validation, Solution and mobile phase stability. 
 
INTRODUCTION 
The Etodolac is widely used in the treatment pain or inflammation 
caused by arthritis or osteoarthritis. Etodolac is non steroidal anti-
inflammatory drug (NASIDs). It works by reducing hormones that 
cause inflammation and pain in the body. In addition, it maintains a 
better physiological regulation of insulin secretion. Etodolac is 
racemic mixture of [+] S and [-]R-Etodolac. Etodolac chemically 
known as 1,8-Diethyl-1,3,4,9-tetrahydropyrano [3,4-b]indole-1-
acetic acid, chemical structures show in (fig. 1), (R)-(-)–Etodolac 
show in (fig. 2) and (S)-(+)–Etodolac show in (fig. 3) It has been 
demonstrated in animal that the [+]S-form is biologically active. 
Several different methods have been reported for qualitative and 
quantitative analysis of Etodolac. These include analysis of chiral 
non-steroidal anti-inflammatory drug [1], Direct high performance 
liquid chromatography separation of etodolac [2], RP-HPLC method 
for the quantization of etodalac in combined Dosage form [3], 
preparative resolution of etodolac enantiomers by preferential 
crystallization method [4], Optical resolution of drug by capillary 
electrophoretic techniques [5], Evaluation of the stero selective 
metabolism of the chiral analgesic drug etodolac [6], Exploration of 
an efficient method for optical resolution of etodolac [7], Enantio 
separation of Anti-Inflammatory Agent on chiral stationary phase 
[8], Determine Bioequivalence of S-Etodolac [9].  
In the literature, there is no method for the separation of R-isomer 
and S-isomer of Etodolac in bulk drugs using reverse phase 
containing buffer 0.1M sodium dihydrogen phosphate dihydrate by 
high performance liquid chromatography. Normal-phase 
chromatography is the most popular mode of liquid chromatography 
at present for separation of isomer. Briefly the major disadvantages 
of normal phase HPLC lie in the highly non-polar nature of the 
mobile phase, the possibility of column inactivation by water, 
contamination by polar compounds and lower potential in terms of 
selectivity. 
This report describes a reverse phase LC method for the rapid 
separation of R-isomer and S-isomer Etodolac. The developed HPLC 
method was validated for quantification of R-isomer in Etodolac as 



























Fig. 3: Chemical structure of (S)-(+)-Etodolac 
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MATERIALS AND METHODS 
Chemicals 
Etodolac racemic, R-isomer and S-isomer were kindly gift by Enal 
lab Mumbai, Maharashtra, India. HPLC grade isopropanol purchased 
from Merck. AR grade Sodium dihydrogen phosphate dihydrate 
purchased from Merck. AR grade ortho phosphoric acid purchased 
from Rankem. HPLC grade methanol purchased from Merck. 
Equipment 
A shimadzu 2010 series LC system with UV detector and inbuilt auto 
injector were utilized for method development and validation. LC 
Solution software was used for data acquisition and system 
suitability calculations.  
Sample preparation 
Stock solutions of Racemic Etodolac (0.1 mg/ml) were prepared by 
dissolving the appropriate amount of the substances in methanol 
and diluent. The analyte concentration of S-isomer was fixed as 0.1 
mg/ml. Working solutions of S-isomer and R-isomer were prepared 
in methanol and diluent. 
Chromatographic conditions 
The chromatographic conditions were optimized using a Chiral-AGP 
Regression curve was obtained by plotting peak area versus 
concentration using the least squares method. Linearity was 
checked for 3 consecutive days in the same concentration range 
from the same stock solution. The percentage relative standard 
deviation of the slope and Y-intercept of the calibration curve was 
calculated.  
(100 x 4.0 mm i. d, 5 µm) column. The mobile phase was 0.1 M 
Sodium dihydrogen phosphate dihydrate pH 4.0 with ortho 
phosphoric acid: IPA (85:15, v/v). Diluents 0.1 M Sodium 
dihydrogen phosphate dihydrate pH 4.0 with ortho phosphoric acid. 
The flow rate was set at 1.0 ml/min. The column was maintained at 
25 ºC and the detection was carried out at a wavelength of 225 nm. 
The injection volume was 10 µl.  
Validation of the method  
Method reproducibility 
Method reproducibility was determined by measuring repeatability 
and intermediate precision (between-days precision) of retention 
times and peak areas for R–isomer and S-isomer. 
In order to determine the repeatability of the method, replicate 
injections (n=6) of a 0.1 mg/ml solution containing S-isomer spiked 
with R-isomer (0.5 %) was carried out. The intermediate precision 
was also evaluated over three days by performing six successive 
injections each day. 
Limit of detection and limit of quantification of R-isomer 
The limit of detection defined as, the lowest concentration of analyte 
that can be clearly detected above the baseline signal, is estimated as 
three times the signal to noise ratio [10]. The limit of quantitation 
defined as, the lowest concentration of analyte that can be quantified 
with suitable precision and accuracy, is estimated as ten times the 
signal to noise ratio [10]. LOD and LOQ were achieved by injecting a 
series of dilute solutions of R-isomer. 
The precision of the developed method for R-isomer at the limit of 
quantification was checked by analyzing six test solutions of R-
isomer prepared at LOQ level and calculating the percentage relative 
standard deviation of an area.  
Linearity of R-isomer 
Detector response linearity was assessed by preparing six 
calibration sample solutions of R-isomer covering from 300 ng/ml 
(LOQ) to 3000 ng/ml (300 ng/ml, 600 ng/ml, 900 ng/ml, 1200 
ng/ml, 1500 ng/ml and 3000 ng/ml), prepared in mobile phase from 
R-isomer stock solution.  
Quantification of R-isomer in bulk sample  
The Etodolac bulk sample gift by Enal Lab Mumbai, showed the 
presence of 0.20 % of R-isomer. Standard addition and recovery 
experiments were conducted to determine the accuracy of the present 
method for the quantification of R–isomer in bulk drug samples. 
The study was carried out in triplicate at 0.2, 0.5 and 0.75 percent of 
the Etodolac target analyte concentration. The recovery of R-isomer 
was calculated from the slope and Y-intercept of the calibration curve.  
Robustness 
The robustness of a method is the ability of the method to remain 
unaffected by small changes in parameters such as flow rate, mobile 
phase composition and column temperature. To determine 
robustness of the method, experimental conditions were purposely 
altered and chromatographic resolution between R-isomer and S-
isomer was evaluated.  
The flow rate of the mobile phase was 1.0 ml/min. To study the 
effect of flow rate on the resolution of isomers, it was changed by 0.2 
units from 0.8 ml/min to 1.2 ml/min. The effects of change in 
percent ethanol on resolution were studied by varying from-1 to+1 
% while the other mobile phase components were held constant as 
stated in section 2.4. The effect of column temperature on the 
resolution was studied at 20 ºC and 30 °C instead of 25 °C while the 
other mobile phase components were held constant. 
Solution stability and mobile phase stability  
Stability of Etodolac in solution at analyte concentration was studied 
by keeping the solutions in tightly capped volumetric flask at room 
temperature on a laboratory bench for two days. Content of R-
isomer was checked for six hours interval up to the study period.  
Mobile phase stability was carried out by evaluating the content of 
R-isomer in Etodolac sample solutions prepared freshly at six hours 
interval for two days. Same mobile phase was used during the study 
period. 
RESULTS AND DISCUSSION  
Method development 
The aim of this work is to separate the R-isomer and S-isomer of 
Etodolac using reverse phase HPLC within short run time, the analysis of 
Etodolac sample using reverse phase is time consuming. A 0.1 mg/ml 
solutions of isomeric mixture prepared in methanol and diluent were 
used in the method development. To develop a rugged and suitable LC 
method for the separation of Etodolac isomer, different mobile phases 
and stationary phases were employed in an attempt to separate the 
isomer of Etodolac. Various experiments were conducted to select the 
best stationary and mobile phases that would give optimum resolution 
and selectivity for the two isomer. The chromatographic separation was 
achieved on a Chiral AGP (100 x 4.0 mm i. d, 5 µm) column using a 
mobile phase system containing 0.1 M Sodium dihydrogen phosphate 
dihydrate pH 4.0: isopropanol (85:15, v/v). 
The flow rate of the mobile phase was 1.0 ml/min. At 25 °C column 
temperature, the peak shape of Etodolac was found symmetrical.  
In the optimized method, the typical retention times of R-isomer 
and S-isomer of Etodolac were about 3.6 and 4.2 minutes 
respectively. The isomeric separation of Etodolac is shown in 
system suitability chromatogram (fig. 4). Typical HPLC 
chromatogram of Etodolac bulk sample (100 µg/ml) spiked with 
R-isomer (0.2 %) shown in (fig. 5).  
Validation results of the method 
The system suitability test results are presented in (Table1). In the 
repeatability study, the relative standard deviation (RSD) was better 
than 0.5 % for the retention times of the isomers, 0.7 % for Etodolac 
peak area and 2.3 % for R-isomer peak area (table 2). In the 
intermediate precision study, results show that RSD values were in 
the same order of magnitude than those obtained for repeatability 
(table 2). 
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Fig. 4: Typical HPLC chromatogram of System suitability 
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Fig. 5: Typical HPLC chromatogram of Etodolac bulk sample (100 µg/ml) spiked with R-isomer (0.2 %) 
 
The limit of detection (LOD) and limit of quantification (LOQ) 
concentrations were estimated to be 300 and 900 ng/ml for R-
isomer, when a signal-to-noise ratio of 3 and 10 was used as the 
criteria. The method precision for R-isomer at the limit of 
quantification was less than 3 % RSD (table 2). 
Good linearity was observed for R isomer over the concentration 
range of 300–3000 ng/ml, with the linear regression equation y = 
36.781X+569 (Correlation coefficient R = 0.999). Linearity was 
checked for R–isomer over the same concentration range for three 
consecutive days. The percentage relative standard deviation of the 
slope and Y-intercept of the calibration curve were 2.1 and 1.6 
respectively (table 2). 
 
Table 1: System-suitability report 
 Compound (n=3) Rt RS N T  
 R-isomer 3.6 - 5100 1.1  
 S-isomer 4.3 3.0 5300 1.1  
n =3 determinations, RS–USP resolution, N-number of theoretical 
plates (USP tangent method), T-USP tailing factor 
 
The standard addition and recovery experiments were conducted 
for R isomer in bulk samples in triplicate at 0.2, 0.5 and 0.75 percent 
of analyte concentration. Recovery was calculated from the slope 
and Y-intercept of the calibration curve obtained in linearity study 
and percentage recovery was ranged from 98.0 to 102.0 (table 3). 
The chromatographic resolution of R-isomer and S-isomer of 
Etodolac peaks was used to evaluate the method robustness under 
modified conditions. The resolution between R-isomer and S-isomer 
of Etodolac was greater than 2.5 under all separation conditions 
tested (table 4), demonstrating sufficient robustness.  
No significant change in the R-isomer content was observed in 
Etodolac sample during solution stability and mobile phase stability 
experiments. Hence Etodolac sample solution and mobile phase are 
stable for at least 48 hours. 
 
Table 2: Validation results of the developed reverse phase 
method 
Validation parameter Results 
Repeatability (n=6, % RSD)  
Retention time (R-isomer) 0.2 
Retention time (S-isomer) 0.3 
Area (R-isomer) 2.3 
Area (S-isomer) 0.5 
Intermediate precision (n=18, % RSD)  
Retention time (R-isomer) 0.3 
Retention time (S-isomer) 0.4 
Area (R-isomer) 2.6 
Area (S-isomer) 0.6 
LOD-LOQ (R-isomer)  
Limit of detection (ng/ml) 200  
Limit of quantification (ng/ml) 600  
Precision at LOQ (% RSD) 2.8 
Linearity (R-isomer)  
Calibration range (ng/ml) 300-3000  
Calibration points 6 
Correlation coefficient 0.999 
Slope (% RSD) 2.1 
Intercept (% RSD) 1.6 
 
 n=3 determinations 
 
Table 3: Recovery results of R-isomer in bulk drugs 
Added (ng) 
(n=3) 
Recovered (ng) % Recovery % RSD 
2001  1962 98.1 2.6 
5010 5102 101.8 2.2 
7510  7502 99.9 2.4 
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Table 4: Robustness of the method 
Parameter USP resolution between R-isomer 
and S-isomer of Etodolac 







20  2.1 
25   3.0 
30 2.8 
Isopropanol percentage 







A novel, simple and rapid enantiomeric separation of Etodolac using 
reverse-phase 0.1 M Sodium dihydrogen phosphate dihydrate pH 
4.0: IPA (85:15, v/v) mobile phase by high-performance liquid 
chromatographic method was developed and validated as per ICH 
guidelines. The method validation was carried out by using Chiral-
AGP column. The developed method can be used for the quantitative 
determination of R-isomer in bulk drug materials in the 
pharmaceutical industry. 
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